FRACTYL HEALTH INC
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
(a)
Disclosure in lieu of reporting on a Current Report on Form 8-K.
None.
(b)
Material changes to the procedures by which security holders may recommend nominees to the board of directors.
None.
(c)
Insider Trading Arrangements and Policies.
During thethree months ended September 30, 2024, (i)Timothy Kieffer, Chief Scientific Officer, adopted a Rule 10b5-1 trading arrangement on September 11, 2024 that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 227,198 shares of the Company’s common stock until September 15, 2025, (ii)Harith Rajagopalan, Chief Executive Officer and Director, adopteda Rule 10b5-1 trading arrangement on September 12, 2024 that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 438,420 shares of the Company’s common stock until March 31, 2025, and (iii) Jay Caplan, President and Chief Product Officer, adopted a Rule 10b5-1 trading arrangement on September 13, 2024 that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 159,173 shares of the Company’s common stock until March 31, 2025.
Other than as described above, no director or officer of the Company adoptedor terminateda "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.